Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Functional polymorphisms in apoptosis pathway genes and survival in patients with gastric cancer.

Gu D, Du M, Tang C, Chu H, Xu Z, Huo X, Gong W, Tang Y, Zhou J, Tong N, Xu Y, Zhang Z, Wang M, Chen J.

Environ Mol Mutagen. 2014 Jun;55(5):421-7. doi: 10.1002/em.21856. Epub 2014 Feb 17.

PMID:
24535941
2.

Functional variants in cell death pathway genes and risk of pancreatic cancer.

Yang M, Sun T, Wang L, Yu D, Zhang X, Miao X, Liu J, Zhao D, Li H, Tan W, Lin D.

Clin Cancer Res. 2008 May 15;14(10):3230-6. doi: 10.1158/1078-0432.CCR-08-0177.

3.

Functional polymorphisms in cell death pathway genes and risk of renal cell carcinoma.

Zhu J, Qin C, Wang M, Yan F, Ju X, Meng X, Ding Q, Li P, Yang J, Cao Q, Zhang Z, Yin C.

Mol Carcinog. 2010 Sep;49(9):810-7. doi: 10.1002/mc.20656.

PMID:
20572163
4.

Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer.

Park JY, Lee WK, Jung DK, Choi JE, Park TI, Lee EB, Cho S, Park JY, Cha SI, Kim CH, Kam S, Jung TH, Jheon S.

Clin Cancer Res. 2009 Mar 1;15(5):1794-800. doi: 10.1158/1078-0432.CCR-08-1770. Epub 2009 Feb 24.

5.

Polymorphisms of death pathway genes FAS and FASL and risk of premalignant gastric lesions.

Hsu PI, Lu PJ, Wang EM, Ger LP, Lo GH, Tsay FW, Chen TA, Yang HB, Chen HC, Lin WS, Lai KH.

Anticancer Res. 2008 Jan-Feb;28(1A):97-103.

6.

Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes.

Li Y, Hao YL, Kang S, Zhou RM, Wang N, Qi BL.

Gynecol Oncol. 2013 Mar;128(3):584-9. doi: 10.1016/j.ygyno.2012.12.002. Epub 2012 Dec 9.

PMID:
23234803
7.

The CASP8 -652 6N insertion/deletion promoter polymorphism is associated with renal cell carcinoma risk and metastasis.

de Martino M, Haitel A, Schatzl G, Klingler HC, Klatte T.

J Urol. 2013 Aug;190(2):717-22. doi: 10.1016/j.juro.2013.01.008. Epub 2013 Jan 9.

PMID:
23313206
8.

Functional polymorphisms in FAS/FASL system increase the risk of neuroblastoma in Chinese population.

Han W, Zhou Y, Zhong R, Wu C, Song R, Liu L, Zou L, Qiao Y, Zhai K, Chang J, Huang L, Liu L, Lu X, Lou J, Yu D, Tan W, Zhang J, Wang H, Miao X.

PLoS One. 2013 Aug 12;8(8):e71656. doi: 10.1371/journal.pone.0071656. eCollection 2013.

9.

Polymorphisms in cell death pathway genes are associated with altered sperm apoptosis and poor semen quality.

Ji G, Gu A, Hu F, Wang S, Liang J, Xia Y, Lu C, Song L, Fu G, Wang X.

Hum Reprod. 2009 Oct;24(10):2439-46. doi: 10.1093/humrep/dep223. Epub 2009 Jun 20.

PMID:
19542541
10.

Association of genetic variants in apoptosis genes FAS and FASL with radiation-induced late toxicity after prostate cancer radiotherapy.

Thurner EM, Krenn-Pilko S, Langsenlehner U, Renner W, Gerger A, Kapp KS, Langsenlehner T.

Strahlenther Onkol. 2014 Mar;190(3):304-9. doi: 10.1007/s00066-013-0485-0. Epub 2014 Jan 16.

PMID:
24424626
11.

Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma.

Zhou RM, Wang N, Chen ZF, Duan YN, Sun DL, Li Y.

J Gastroenterol Hepatol. 2010 Mar;25(3):555-61. doi: 10.1111/j.1440-1746.2009.06116.x. Epub 2010 Jan 13.

PMID:
20074157
12.

Caspase 8 and caspase 9 gene polymorphisms and susceptibility to gastric cancer.

Liamarkopoulos E, Gazouli M, Aravantinos G, Tzanakis N, Theodoropoulos G, Rizos S, Nikiteas N.

Gastric Cancer. 2011 Oct;14(4):317-21. doi: 10.1007/s10120-011-0045-1. Epub 2011 Apr 2.

PMID:
21461653
13.

FAS and FAS ligand polymorphisms in the promoter regions and risk of gastric cancer in Southern China.

Wang M, Wu D, Tan M, Gong W, Xue H, Shen H, Zhang Z.

Biochem Genet. 2009 Aug;47(7-8):559-68. doi: 10.1007/s10528-009-9264-0. Epub 2009 Jun 30.

PMID:
19565204
14.

Single-nucleotide gene polymorphisms involving cell death pathways: a study of Chinese patients with lumbar disc herniation.

Sun Z, Ling M, Chang Y, Huo Y, Yang G, Ji Y, Li Y.

Connect Tissue Res. 2013;54(1):55-61. doi: 10.3109/03008207.2012.734878. Epub 2012 Dec 3.

PMID:
23205884
15.

A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer.

Sung WW, Wang YC, Cheng YW, Lee MC, Yeh KT, Wang L, Wang J, Chen CY, Lee H.

Clin Cancer Res. 2011 Sep 15;17(18):5991-9. doi: 10.1158/1078-0432.CCR-11-0227. Epub 2011 Aug 1.

16.

Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.

Zhang B, Sun T, Xue L, Han X, Zhang B, Lu N, Shi Y, Tan W, Zhou Y, Zhao D, Zhang X, Guo Y, Lin D.

Carcinogenesis. 2007 May;28(5):1067-73. Epub 2006 Dec 20.

PMID:
17183065
17.

[Genetic polymorphisms of apoptosis-associated genes FAS and FASL and risk of colorectal cancer].

Yang S, Miao XP, Zhang XM, Sun T, Qu SN, Xiong P, Ye YJ, Guo YL, Tan W, Wang S, Lin DX.

Zhonghua Yi Xue Za Zhi. 2005 Aug 10;85(30):2132-5. Chinese.

PMID:
16313826
18.

Functional polymorphisms in FAS, FASL and CASP8 genes and risk of childhood acute lymphoblastic leukemia: a case-control study.

Tong N, Zhang L, Sheng X, Wang M, Zhang Z, Fang Y, Xue Y, Li J, Zhang Z.

Leuk Lymphoma. 2012 Jul;53(7):1360-6. doi: 10.3109/10428194.2011.654117. Epub 2012 Jan 31.

PMID:
22211869
19.

Polymorphisms in the apoptosis-associated genes FAS and FASL and risk of oral cancer and malignant potential of oral premalignant lesions in a Taiwanese population.

Wang LH, Ting SC, Chen CH, Tsai CC, Lung O, Liu TC, Lee CW, Wang YY, Tsai CL, Lin YC.

J Oral Pathol Med. 2010 Feb;39(2):155-61. doi: 10.1111/j.1600-0714.2009.00873.x.

PMID:
20359312
20.

Susceptibility to oral cancers with CD95 and CD95L promoter SNPs may vary with the site and gender.

Daripally S, Nallapalle SR, Katta S, Prasad VV.

Tumour Biol. 2015 Sep;36(10):7817-30. doi: 10.1007/s13277-015-3516-x. Epub 2015 May 6.

PMID:
25944167

Supplemental Content

Support Center